Rocket Pharmaceuticals (RCKT) Cash & Equivalents (2014 - 2026)

Rocket Pharmaceuticals has reported Cash & Equivalents for 13 years, with the latest figure at $144.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 189.9% year-over-year to $144.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $144.4 million (up 189.9% YoY) and the FY2025 annual result came in at $77.6 million, down 52.6% from the prior year.
• Cash & Equivalents rose to $144.4 million in Q1 2026 per RCKT's latest filing, from $77.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $437.2 million in Q3 2023 and troughed at $32.8 million in Q2 2025.
• A 5-year average of $181.4 million and a median of $144.4 million in 2026 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 518.51% in 2024, down 90.2% in 2024.
• Over 5 years, Cash & Equivalents stood at $140.5 million in 2022, then sank by 60.22% to $55.9 million in 2023, then surged by 192.71% to $163.6 million in 2024, then slumped by 52.6% to $77.6 million in 2025, then surged by 86.18% to $144.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $144.4 million, $77.6 million, and $222.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.